Earnings Summary

Ultragenyx Pharmaceutical Inc.’s revenue jumped 42.27% since last year same period to $139.49Mn in the Q3 2024. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated -5.12% fall in its revenue since last 3-months.

Ultragenyx Pharmaceutical Inc.’s net profit jumped 16.37% since last year same period to $-133.52Mn in the Q3 2024. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated -1.46% fall in its net profits since last 3-months.

Ultragenyx Pharmaceutical Inc.’s net profit margin jumped 41.21% since last year same period to -95.71% in the Q3 2024. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated -6.94% fall in its net profit margins since last 3-months.

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) estimates for the current year stand at -1.75.

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) jumped 37.22% since last year same period to -1.4 in the Q3 2024. This indicates that the Ultragenyx Pharmaceutical Inc. has generated 37.22% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ultragenyx Pharmaceutical Inc.’s return on assets (ROA) stands at -0.24.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ultragenyx Pharmaceutical Inc.’s return on equity (ROE) stands at -2.9.